A 1:30 p.m. Pacific call is planned to discuss Freenome's third-quarter results on Nov. 10.
Freenome (FRNM) will release Q3 2026 results on Nov. 10 after market close, followed by a call at 1:30 PM PT. The company develops blood-based cancer detection tests, including SimpleScreen CRC for colorectal cancer.
How this was made
The 30-second read
Why it matters
The main tradable element is the earnings catalyst timing, which can drive pre-positioning and after-hours repricing once results are released.
Market read
Sets the next earnings event window for FRNM, which can increase near-term volatility and options activity into the Nov. 10 release.
What to watch
Traders should focus on what is likely to be emphasized on the call (test performance, pipeline timelines, and cash runway), but those details are not provided here.
Background
Freenome is an early cancer detection company developing blood-based screening tests and a multiomics platform.
Ticker impact
Freenome (FRNM) scheduled its Q3 2026 results release after the close on Nov. 10 and a 1:30 p.m. PT call to discuss them.
Likely volatility around the Nov. 10 after-hours earnings release as traders position for Q3 results and management commentary.
The article discloses only the timing of the earnings release and conference call, with no new financial figures or guidance.
Market effects
Adds another near-term catalyst for the early cancer detection and diagnostics cohort, but without sector-wide new information.
No direct regional macro linkage beyond standard US biotech earnings calendar effects.
Limited, as the disclosure is company-specific and not tied to global regulatory or trial milestones.
Counterpoint
Because the release date is already a calendar item, the incremental trading edge may be small unless the market expects a major surprise.
Key entities
- companyFreenome, Inc.
Nasdaq-listed early cancer detection company planning to release Q3 2026 results on Nov. 10 and hold a conference call at 1:30 p.m. PT.
